Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.
J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.
Similar articles
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI.
Urology. 2008 Jul;72(1):172-6. doi: 10.1016/j.urology.2007.10.055. Epub 2008 Mar 4.
Causes of death after radical prostatectomy at a large tertiary center.
Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M.
J Urol. 2012 Sep;188(3):798-801. doi: 10.1016/j.juro.2012.04.109. Epub 2012 Jul 20.
The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.
Eur Urol. 2015 Feb;67(2):342-6. doi: 10.1016/j.eururo.2014.06.015. Epub 2014 Jun 23.
What are the outcomes of radical prostatectomy for high-risk prostate cancer?
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC.
Urology. 2010 Sep;76(3):710-4. doi: 10.1016/j.urology.2009.09.014. Epub 2009 Nov 22.
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.
J Urol. 2008 May;179(5):1780-4; discussion 1784. doi: 10.1016/j.juro.2008.01.032. Epub 2008 Mar 17.
Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.
Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE.
J Urol. 2017 Jan;197(1):122-128. doi: 10.1016/j.juro.2016.08.091. Epub 2016 Aug 26.
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW.
Urology. 2007 Jun;69(6):1095-101.
Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.
Urology. 2008 Dec;72(6):1246-51. doi: 10.1016/j.urology.2008.01.052. Epub 2008 Apr 2.
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC.
J Urol. 2004 Nov;172(5 Pt 1):1860-4.
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW.
Urology. 2001 Nov;58(5):746-51.
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary.
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.
J Urol. 2012 Dec;188(6):2219-24. doi: 10.1016/j.juro.2012.08.028. Epub 2012 Oct 22.
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB.
J Urol. 2013 Oct;190(4):1218-22. doi: 10.1016/j.juro.2013.04.071. Epub 2013 Apr 30.
Obesity and long-term survival after radical prostatectomy.
Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.
J Urol. 2014 Oct;192(4):1100-4. doi: 10.1016/j.juro.2014.04.086. Epub 2014 Apr 21.
Can we stop prostate specific antigen testing 10 years after radical prostatectomy?
Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC.
J Urol. 2011 Aug;186(2):500-5. doi: 10.1016/j.juro.2011.03.116. Epub 2011 Jun 15.
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML.
J Urol. 2007 Oct;178(4 Pt 1):1311-5. Epub 2007 Aug 16.
The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.
J Urol. 2017 Apr;197(4):1060-1067. doi: 10.1016/j.juro.2016.11.079. Epub 2016 Nov 12.
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.
J Urol. 2012 Oct;188(4):1131-6. doi: 10.1016/j.juro.2012.06.009. Epub 2012 Aug 15.
Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.
Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI.
J Urol. 2014 Oct;192(4):1081-7. doi: 10.1016/j.juro.2014.04.013. Epub 2014 Apr 18.
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW.
Urology. 2006 Jan;67(1):115-9.
Filters: Manage Filters